TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating on April 29.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marc Frahm has given his Buy rating due to a combination of factors tied to Black Diamond Therapeutics’ lead asset and financial position. He highlights silevertinib (BDTX-1535) as a differentiated, CNS-penetrant EGFR inhibitor with broad activity across non-classical EGFR-mutant NSCLC, including strong responses in brain metastases, and sees upcoming ASCO DOR/PFS data as a key catalyst that could reinforce its competitiveness despite prior concerns about dose reductions and rival therapies.
He also notes that the company’s cash balance of roughly $118 million provides runway into the second half of 2028, supporting both regulatory interactions and clinical execution. In parallel, the initiation of a randomized Phase 2 trial in EGFR-mutant GBM, with PFS data expected in the first half of 2028, offers an additional value driver, and potential partnership structures for a pivotal NSCLC program could preserve long-term upside, collectively justifying a continued Buy stance.
In another report released on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.